Form 13-F position report

ROCKET PHARMACEUTICALS INC COM

Reported by M28 Capital Management LP

Company profile Manager portfolio Source filing
RCKT CUSIP 77313F106 Manager CIK 0001807489
Latest reported change

Reported 523,280 shares, unchanged from the prior quarter.

Reported value 46.3%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 12.99% This manager · Q4 2023
Shares 523,280 Quarter-end amount reported
Reported value $15,682,702 Fair value at quarter end
Consecutive quarters held 9 Through Q4 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Unchanged 210,871 0 (0.0%) 1.53% $721,179 2026-08-13
Q1 2026 Reduced 210,871 -174,809 (-45.3%) 1.4% $754,918 2026-05-14
Q4 2025 Unchanged 385,680 0 (0.0%) 0.98% $1,353,737 2026-02-13
Q3 2025 Unchanged 385,680 0 (0.0%) 1.85% $1,257,317 2025-11-13
Q2 2025 Unchanged 385,680 0 (0.0%) 1.61% $944,916 2025-08-13
Q1 2025 Unchanged 385,680 0 (0.0%) 3.53% $2,572,486 2025-05-14
Q4 2024 Unchanged 385,680 0 (0.0%) 4.76% $4,847,998 2025-02-13
Q3 2024 Unchanged 385,680 0 (0.0%) 7.83% $7,123,510 2024-11-12
Q2 2024 Unchanged 385,680 0 (0.0%) 10.76% $8,303,690 2024-08-13
Q1 2024 Reduced 385,680 -137,600 (-26.3%) 7.68% $10,390,219 2024-05-14
Q4 2023 Unchanged 523,280 0 (0.0%) 12.99% $15,682,702 2024-02-12
Q3 2023 Reduced 523,280 -107,100 (-17.0%) 12.3% $10,722,007 2023-11-13
Q2 2023 Reduced 630,380 -91,700 (-12.7%) 16.55% $12,525,651 2023-08-11
Q1 2023 Unchanged 722,080 0 (0.0%) 13.99% $12,369,230 2023-05-12
Q4 2022 Added 722,080 +56,200 (8.4%) 13.47% $14,131,106 2023-02-10
Q3 2022 Reduced 665,880 -50,000 (-7.0%) 11.09% $10,627,000 2022-11-10
Q2 2022 Unchanged 715,880 0 (0.0%) 11.04% $9,851,000 2022-08-12
Q1 2022 Added 715,880 +220,600 (44.5%) 10.44% $11,354,000 2022-05-13
Q4 2021 New 495,280 +495,280 (0.0%) 8.44% $10,812,000 2022-02-11
Institutional context

Who else reported the position

215 managers reported ROCKET PHARMACEUTICALS INC COM for Q4 2023.

Manager Activity Shares Change % of reported 13F Reported value Tenure
RTW INVESTMENTS LP Unchanged 17,687,772 0 8.28% $530,102,527 24 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 8,197,546 +174,716 0.05% $245,680,453 20 qtrs
BlackRock Inc Added 5,930,178 +816,551 < 0.01% $177,727,435 24 qtrs
VANGUARD GROUP INC Added 5,447,565 +843,552 < 0.01% $163,263,523 24 qtrs
MAVERICK CAPITAL LTD Reduced 4,034,068 -1,595,902 2.43% $120,901,018 11 qtrs
WESTFIELD CAPITAL MANAGEMENT CO LP Reduced 3,941,859 -252,137 0.69% $118,137,514 19 qtrs
STATE STREET CORPORATION Added 3,231,411 +91,906 < 0.01% $96,845,388 23 qtrs
PRICE T ROWE ASSOCIATES INC MD Reduced 2,629,074 -8,877 0.01% $78,794,000 24 qtrs
CITADEL ADVISORS LLC Reduced 2,457,561 -220,940 0.01% $73,653,104 24 qtrs
Avidity Partners Management LP Added 1,719,103 +131,674 1.88% $51,521,517 5 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2023
Filed
February 12, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
523,280
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.